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Regional IssuesThe ultimate goal of generating evidence in health economics
and outcomes research is to improve population health by
affecting policy and system change. Belief among policymakers,
researchers, and academics in using scientiﬁc research-based
evidence for efﬁcient allocation of scarce health resources has
been widespread in recent years at a global level [1–3]. Value in
Health Regional Issues (ViHRI) understands this signiﬁcance of
scientiﬁc research in generating evidence and its impact on
resource allocation.
From a wide spectrum of gathered evidence, the focus of ViHRI
was placed on health technology–related pharmacoeconomics
and outcomes research and its associated topics in the beginning
years of 2012 and 2013. As ViHRI for Asia enters its third year, it is
time to review what has been achieved thus far and revisit
research directives for the coming years.
Over the past 2 years, we have observed a signiﬁcant increase
in the number of submitted articles. Even more encouraging,
however, is the corresponding advancement in the quality of
articles, including in methodology, data reliability, data analyses,
number of disease categories studied, and diversity of target
populations. ViHRI Asia 2014 received 73 manuscript submis-
sions, which was a 9% increase from the 67 manuscript submis-
sions received for the 2013 Asia issue. Of 73 manuscripts
submitted for this issue, 31 were accepted (42% acceptance rate),
34 were rejected, 4 were withdrawn, 3 are being revised for
consideration for 2015, and 1 has been recommended for sub-
mission to ISPOR CONNECTIONS.
The number of accepted articles had been limited in previous
issues (22 articles for the ﬁrst ViHRI Asia Special Issue, 24 for the
second, 20 for the third, 20 for the ViHRI Asia 2012, and 23 for the
ViHRI Asia 2013) for two reasons: limited physical space for
publication and shortage of quality manuscripts. With the sig-
niﬁcant increase in submission of quality manuscripts this year,
we needed to address only the space limitation issue, which has
been overcome by shifting the journal to being an online
publication starting 2014.
Manuscripts for this volume were submitted from a diverse
geographic range, including Iran, India, the Philippines, Viet-
nam, Thailand, Malaysia, mainland China, Singapore, Taiwan,
Hong Kong, Japan, and South Korea. We observed that authors
from Asia-Paciﬁc regions not only were able to conduct high-
quality clinical trials and ﬁeld questionnaires but also used
sophisticated electronic hospital patient records, health insur-
ance medical claims, and advanced statistical methods and
modeling. Many topics are timely and carry signiﬁcance forst: The authors have indicated that they have no
ial support: The authors have no other ﬁnancial rclinical and policy decision making for health care agencies,
care providers, policymakers, consulting ﬁrms, and the pharma-
ceutical industry.
Our accepted manuscripts for this volume cover broad-
spectrum topics such as health policy, health economics,
patient-reported outcomes, medication compliance, research
methodology, conceptual articles, epidemiology, patient safety,
and other clinical outcomes. Therapeutic areas covered are also
broad, from hepatitis, diabetes mellitus, coronary heart disease,
cancer, to even traditional oriental medicine, which is of parti-
cular interest to Asian populations. Furthermore, studies such as
the cost-effectiveness of a public dental management program
(Mohd-Dom), effect of diabetes on quality of life in patients with
coronary artery disease (Shah), health outcome of elderly
patients taking both Western drugs and traditional Chinese
medicines (Lin), and predicting the burden of cardiovascular
disease risk in rural areas (Nguyen) are examples of interesting
topics and research approaches that will be found in the ViHRI
Asia 2014 issue.
Although most of the studies included in this volume are
typical of health economics and outcomes research, we have also
included more health system and policy research studies, such as
one study exploring the perspective of a small group of stake-
holders involved in health technology assessment (HTA) for
evidence-informed decision making in India (Bhavesh), another
study attempting to understand the HTA environment in several
Asian countries and its implications for disease treatment (Ken-
nedy-Martin), and one introducing the drug regulatory and
reimbursement system in Iran (Ansaripour). Health system and
policy research has received global attention, as evidenced by the
establishment of the Alliance for Health Policy and Systems
Research, and a series of global symposiums in health systems
research in 2010, 2012, and 2014. In this volume, we strive to
reﬂect the global interest in this area, with limited scope of HTA
though.
Given the diversity of the Asian countries in socioeconomic
status, culture, and preferences and attitudes of different jur-
isdictions, it is anticipated that the results and conclusions
arising from one study will ﬁnd it difﬁcult to generalize to
another country. Nevertheless, there are certain principles that
are believed to be cross-country and cross-culture. These include
evidence-based decision making, health beneﬁts only established
by long-term evaluation, reallocation of resources from cost-
ineffective to cost-effective technologies and interventions, and
maximizing health gains by relying on efﬁciency evidence. Forconﬂicts of interest with regard to the content of this article.
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their research skills, it is also encouraged that they should
perform more policy research for study results to be incorporated
into policies at both local and regional levels, with the ultimate
objective of attaining an efﬁciency gain in health care delivery.
Additional related avenues of research to these issues would be
the development of prediction models that can be applied in
neighboring countries in Asia, analyses of databases that are
common across different organizations, and simultaneous com-
parison of speciﬁc technologies among countries.
We feel that for researchers in Asia, it is of particular impor-
tance at this juncture to pursue the goal of attaining an efﬁciency
gain in overall health care delivery, which can be achieved only by
conducting more policy research to produce data that will inform
policy change and formation. Policy research in Asia should
preferably center around the disease states leading to improve-
ment in key health metrics such as life expectancy and infant
mortality, which are of relatively higher priority for most devel-
oping countries. The HTA program can speciﬁcally identify the
areas of currently underutilized health care services that would
certainly contribute to health metrics in the long run. With the
emergence of more biologics and new oncology agents, Asian
countries also need to research whether to have a ﬁxed incre-
mental cost-effectiveness ratio (ICER) for all new technologies, or
to allow a ﬂexible ICER in addition to a ﬁxed one to cater to the
more expensive innovative products. For example, although per-
sonalized medicine is slowly expanding its horizon in some Asian
countries, none of these countries has a pertinent pharmacoeco-
nomics submission guideline for biomarkers’ coverage and reim-
bursement for related health gains in place.
Transferability of outcomes data and epidemiological data is
another area of challenge for Asian countries. Drummond [4]
hinted at allowing for more exploration of differences in relative
treatment effects across regions, countries, and settings. Utiliza-
tion and cost data are known to be context-speciﬁc. There are
wide variations, however, in the availability of resource use and
costs data in Asia, with Korea and Taiwan on one extreme with
national e-databases, while countries with private sector delivery
without public payers are on the other extreme of having scant
databases. Building up basic data infrastructure for evidence
generation is a challenge that most Asian nations face.
Furthermore, ﬁnding proper utility values for local reimburse-
ment decision frameworks is a formidable challenge to most HTA
agencies in Asia. Most of the studies in Asia use utility values
taken from the existing literature or from studies done in
different settings with different instruments. Considering that
utility weights play a critical role in setting ICER values, for fair
and just resource allocation decisions, there exists a strong needfor discussions on the transferability of utility values across
countries and regions, and on how to come up with appropriate
utility values at local settings. An article in relation to this topic
appears in the current issue (Azuma). But more discussion and
research in this regard are expected among countries in Asia.
It is clear that collaborative effort from across the Asian region
is called for. This presents an extra challenge in comparison to
research conducted on individual technologies under a speciﬁc
environment. In the long run, however, this will not only beneﬁt
individual organizations and governments but also Asia as a
whole. Now, we are ready to move onto the second phase of
ViHRI, in which publication of rich evidence will make ViHRI a
highly regarded and frequently read international journal in the
ﬁeld of pharmacoeconomics and outcomes research and health
policy.
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